MarketPR
GEGE Aerospace raises 2026 guidance on record engine ordersOct 21INSMInsmed adds Sanofi and Verily executives to boardOct 21MAMastercard Q2 Revenue Beats Gross Dollar Volume GrowthOct 21REGULATORYKiffin blames SEC schedule for LSU strugglesOct 21EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21SHFSNasdaq grants Safe Harbor Financial extra 180 days to meet bid priceOct 21INDPIndaptus Therapeutics completes $24 million private placementOct 21JEFJefferies discloses recent share repurchases at investor meetingOct 20LNZALanzaTech Global Files 8-K for LanzaJet Recapitalization and $10M Note IssuanceOct 20GEGE Aerospace raises 2026 guidance on record engine ordersOct 21INSMInsmed adds Sanofi and Verily executives to boardOct 21MAMastercard Q2 Revenue Beats Gross Dollar Volume GrowthOct 21REGULATORYKiffin blames SEC schedule for LSU strugglesOct 21EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21SHFSNasdaq grants Safe Harbor Financial extra 180 days to meet bid priceOct 21INDPIndaptus Therapeutics completes $24 million private placementOct 21JEFJefferies discloses recent share repurchases at investor meetingOct 20LNZALanzaTech Global Files 8-K for LanzaJet Recapitalization and $10M Note IssuanceOct 20
NewsHealth

Latin American dementia-prevention study replicates POINTER outcomes at AAIC

A study testing lifestyle-based dementia risk-reduction strategies in Latin America has been called a "landmark" effort after its findings replicated the direction of the U.S. POINTER trial, according to Day 2 reporting from the Alzheimer's Association International Conference. The Alzheimer's Association's Maria Carrillo announced at Monday's plenary that 10,200 attendees from 115 countries are present this year, 1,700 more than last year's conference. For a disease that has proven intractable to treat, a behavioral finding that holds across two independent trials and two separate populations is a different kind of signal than a single-study result.

By Desmond ChoiNewsroomJuly 13, 20262 min read
Share

Key takeaways

  • A Latin American lifestyle-based dementia risk-reduction study replicated the direction of benefit found in the U.S. POINTER trial, and was described as a "landmark" effort in Day 2 AAIC reporting.
  • The U.S. POINTER trial found older at-risk adults in an intensive, structured program covering diet, exercise, and cardiovascular monitoring showed greater cognitive protection than those in a self-directed program.
  • The Latin American study's full details—including enrollment size, specific endpoints, and effect sizes—are behind a STAT+ paywall and absent from the session summary.
  • This year's Alzheimer's Association International Conference drew 10,200 attendees from 115 countries, 1,700 more than last year.
  • Full publication of the Latin American study is the confirmable next milestone, enabling direct endpoint comparison with POINTER and independent peer review.

A study testing lifestyle-based dementia risk-reduction strategies in Latin America has been called a "landmark" effort after its findings replicated the direction of the U.S. POINTER trial, according to Day 2 reporting from the Alzheimer's Association International Conference. The Alzheimer's Association's Maria Carrillo announced at Monday's plenary that 10,200 attendees from 115 countries are present this year, 1,700 more than last year's conference. For a disease that has proven intractable to treat, a behavioral finding that holds across two independent trials and two separate populations is a different kind of signal than a single-study result.

What the POINTER trial found

The U.S. POINTER study, reported at last year's AAIC, set up two arms among older adults considered at risk for dementia. One group followed an intensive, structured program covering improved diet, exercise, cardiovascular health monitoring, and additional steps. The second group navigated a lower-intensity program on their own. Both arms saw some benefits. Participants in the intensive program showed greater protection of cognitive function than those in the self-directed group.

That result built on a recognized set of modifiable risk factors. Poor nutrition, poor sleep, limited cardiovascular health, physical inactivity, low social engagement, and lower education levels each carry documented associations with higher Alzheimer's risk. POINTER's design addressed those factors together rather than one at a time.

What the replication adds

Reproducing a direction of benefit in a geographically and demographically distinct cohort takes a single-trial signal and gives it cross-population weight. The Latin American study's full details are behind a STAT+ paywall, meaning enrollment size, specific endpoints, and effect sizes are absent from the session summary. How closely the study's methodology mirrors POINTER's will matter when the paper reaches peer review. A p-value in one population is a clue. The same direction reproduced elsewhere starts to look like a pattern worth building on.

What to watch

Additional data presentations are expected through the week at AAIC. STAT signaled conference coverage for Tuesday morning around 9:15 a.m. Eastern at statnews.com, with a newsletter wrap-up planned for Wednesday. The confirmable next milestone is full study publication, which would allow a direct comparison of endpoints between the Latin American replication and the original POINTER trial and put the methodology in front of independent review.

About this story

Filed by the newsroom of MarketPR on July 13, 2026. Source: statnews.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Health

FDA forms board to guide drug exclusivity rulings

The U.S. Food and Drug Administration Center for Drug Evaluation and Research has created a board to oversee and advise on exclusivity decisions, a move Reuters reports is intended to improve the clarity and consistency of those…

Renata Ostrowski2 min read
02Health

STAT+ column highlights learned helplessness in physician training

STAT+ has launched a new column, Chief Complaint, written by Frances Mei Hardin, M.D., a former ear, nose, and throat surgeon. The inaugural piece addresses the psychological state of learned helplessness among physicians, arguing that…

Talia Greenwood2 min read
03Health

MAHA movement struggles to find footing ahead of midterm elections

The Make America Healthy Again movement, led by Health Secretary Robert F. Kennedy Jr., is facing difficulties establishing a financial and messaging presence in key races as the November 3 midterm elections approach. Despite an initial…

Grant Halloran2 min read

Frequently asked

Why is the Latin American study considered significant?

Because it reproduced the direction of benefit from the U.S. POINTER trial in a geographically and demographically distinct population, giving the single-trial signal cross-population weight rather than a single-study result.

What modifiable risk factors did the POINTER trial address?

POINTER targeted factors together including poor nutrition, poor sleep, limited cardiovascular health, physical inactivity, low social engagement, and lower education levels, each associated with higher Alzheimer's risk.

What details about the Latin American study are still unknown?

Its enrollment size, specific endpoints, and effect sizes are not available because the full details are behind a STAT+ paywall, and how closely its methodology mirrors POINTER's remains to be seen at peer review.

What additional AAIC coverage is planned?

STAT signaled conference coverage for Tuesday morning around 9:15 a.m. Eastern at statnews.com, with a newsletter wrap-up planned for Wednesday, and additional data presentations are expected through the week.